Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;31(1):23-8.
doi: 10.4103/0970-2113.125889.

Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India

Shanmugapriya Shankar  1 , Vijayalakshmi Thanasekaran  2 , T Dhanasekar  2 , Prathiba Duvooru  1
Affiliations

Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India

Shanmugapriya Shankar et al. Lung India. 2014 Jan.

Abstract

Background: Lung cancer is a highly aggressive malignancy causing high morbidity and mortality. An increasing incidence of lung cancer has been observed in India. Currently, the classification of lung carcinoma has gone beyond small cell lung carcinoma and non-small cell lung carcinoma (NSCLC). Precise subtyping of poorly differentiated NSCLC into adenocarcinoma and squamous cell carcinoma has a direct impact on patient management and prognosis. With this background, many molecules are under study for developing targeted therapies. Epidermal growth factor receptor (EGFR) is one such biomarker considered to be useful in targeted therapy for adenocarcinoma.

Objective: The aim of this study was to subtype poorly differentiated NSCLC based on the expression of thyroid transcription factor-1 (TTF-1) and p-63 and to evaluate EGFR expression in adenocarcinomas.

Materials and methods: A retrospective analysis of 84 cases of poorly differentiated carcinomas of the lung was performed. Paraffin sections were immunostained with TTF-1 and p-63 and the tumors were subtyped. EGFR expression was assessed in adenocarcinomas by immunohistochemistry.

Results: Fifty-five percent of the NSCLC were adenocarcinoma, with a peak incidence between 61 and 70 years of age and a male predominance. EGFR was expressed in 89% of the adenocarcinomas.

Conclusions: Poorly differentiated non-small cell carcinoma can be subtyped by immunohistochemical markers and hence has a direct impact on the current therapeutic strategies.

Keywords: Epidermal growth factor receptor; TTF-1; lung carcinomas; p-63.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Chart 1
Chart 1
Prevalence of lung carcinoma
Figure 1
Figure 1
Microphotograph of adenocarcinoma (hematoxylin and eosin, ×200)
Chart 2
Chart 2
Demographic profile based on gender distribution
Chart 3
Chart 3
Age-wise distribution of non-small cell lung carcinoma
Figure 2
Figure 2
Microphotograph of adenocarcinoma (thyroid transcription factor-1, ×200)
Figure 3
Figure 3
Microphotograph of adenocarcinoma (epidermal growth factor receptor, ×200)
Figure 4
Figure 4
Microphotograph of squamous cell carcinoma (hematoxylin and eosin, ×100)
Figure 5
Figure 5
Microphotograph of squamous cell carcinoma (p-63, ×100)
Chart 4
Chart 4
Subtyping of non-small cell lung carcinoma
Chart 5
Chart 5
Immunohistochemical scoring of epidermal growth factor receptor in adenocarcinoma
Chart 6
Chart 6
Distribution of epidermal growth factor receptor in adenocarcinoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rawat J, Sindhwani G, Gaur D, Dua R, Saini S. Clinico-pathological profile of lung cancer in Uttarakhand. Lung India. 2009;26:74–6. - PMC - PubMed
    1. Kumar BS, Abhijit M, Debasis D, Abinash A, Ghoshal AG, Kumar DS. Clinicopathological profile of lung cancer in a tertiary medical centre in India: Analysis of 266 cases. J Dent Oral Hyg. 2011;3:30–3.
    1. de Mello RA, Marques DS, Medeiros R, Araujo AM. Epidermal growth factor receptor and K-ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol. 2011;2:367–76. - PMC - PubMed
    1. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–92. - PubMed
    1. Dacic S. Molecular Diagnostics of lung carcinomas. Arch Pathol Lab Med. 2011;135:622–9. - PubMed